

## WARFARIN AND VITAMIN K ACCELERATE PROTEIN AND GLYCOPROTEIN

SYNTHESIS IN ISOLATED RAT LIVER MITOCHONDRIA IN VITRO<sup>1</sup>Ralph J. Bernacki and H. Bruce Bosmann<sup>2</sup>

Department of Pharmacology and Toxicology  
University of Rochester  
School of Medicine and Dentistry  
Rochester, New York 14620

Received September 18, 1970

Summary: Protein and glycoprotein synthesis is accelerated by vitamin K<sub>1</sub> and warfarin in isolated rat liver mitochondria and slightly accelerated in rat liver microsomes and brain mitochondria in vitro. At  $2 \times 10^{-3}$  M vitamin K<sub>1</sub>, protein synthesis increased 5 fold and glycoprotein synthesis 7 fold in isolated rat liver mitochondria. There is no concomitant increase in RNA and DNA synthesis in the isolated rat liver mitochondria with vitamin K<sub>1</sub> or warfarin. Cycloheximide has no effect on this increase in mitochondrial protein and glycoprotein synthesis in the rat liver mitochondria but chloramphenicol completely abolishes the increase. Conversely, L5178Y mouse leukemia cell macromolecular synthesis is greatly inhibited by vitamin K<sub>1</sub> and warfarin.

Earlier workers have thought that either the liver mitochondria or microsomes may be associated with the production of prothrombin and other clotting factors in vitro and in vivo (1-3). Studies involving vitamin K in protein synthesis, at the level of ATP generation, have been reported (4) but the evidence for a molecular action of vitamin K is contradictory (5). Recent reports showed the reversal of cycloheximide inhibition of prothrombin biosynthesis in vitro (6) and in vivo (3,7) with the addition of vitamin K. The present report shows an acceleration of protein and glycoprotein synthesis in rat liver and brain mitochondria and rat liver microsomes by vitamin K<sub>1</sub> (Aquamephyton<sup>R</sup>) and sodium warfarin (Coumadin<sup>R</sup>).

<sup>1</sup> Supported in part by Grant No. P529 from the American Cancer Society, Grant No. 1-P11-GM-15190 from the National Institutes of Health and Training Grant No. 5-T01-GM-00032 from the National Institutes of Health.

<sup>2</sup> HBB is a Research Career Development Awardee of The National Institute of General Medical Sciences.

Mitochondria are capable of the autonomous synthesis of nucleic acids (8-10), lipids (11, 12), glycolipids (13, 14), proteins (14-18) and glycoproteins (14, 19). Although these macromolecules are presumably synthesized for the mitochondria's own use, it is not inconceivable that the mitochondria provide some precursor type of protein or glycoprotein for the formation or activation of other macromolecules (e.g. proteins, glycoprotein, or enzyme) that the intact cell later secretes, e.g. prothrombin. Recent studies (20, 21) have shown that cycloheximide does not inhibit liver mitochondrial protein or glycoprotein synthesis but does inhibit liver microsomal protein synthesis, and that chloramphenicol does inhibit protein and glycoprotein synthesis in liver mitochondria but has no effect on microsomal protein synthesis. These findings initiated the present study on the effects of vitamin K<sub>1</sub> on rat liver and brain mitochondrial and microsomal synthesis of protein and glycoprotein.

#### Materials and Methods

The rat liver mitochondria were isolated by a modification of the method of Schneider and Hogeboom (22) as previously described (19). Rat liver microsomes were prepared by a modification of the method of Schneider and Kuff (23). pH 5 enzymes prepared separately were precipitated by the addition of 1 M acetic acid to the 140,000 x g supernatant.

Intraneural mitochondria of the rat were prepared by a modification of the method previously described (14).

Uridine diphosphate glucose-<sup>14</sup>C (sp. ac. 200 C<sub>1</sub>/Mole), glucosamine-<sup>14</sup>C (sp. ac. 10 C<sub>1</sub>/Mole), 1-fucose-<sup>3</sup>H (sp. ac. 10 C<sub>1</sub>/Mole), uridine-<sup>3</sup>H (10 C<sub>1</sub>/mMole), thymidine-<sup>3</sup>H (15 C<sub>1</sub>/mMole) and 1-leucine-<sup>14</sup>C (sp. ac. 250 C<sub>1</sub>/Mole) were purchased from New England Nuclear Corp.

Protein determinations were made by the procedure of Lowry *et al.* (22). Protein and glycoprotein synthesis was determined as previously described (14, 19).

#### Results and Discussion

Liver mitochondria showed the greatest acceleration of protein and glyco-

Table 1. Acceleration of incorporation of leucine- $^{14}\text{C}$  and monosaccharide- $^{14}\text{C}$  into protein and glycoprotein by isolated mitochondria and microsomes. Data are given as pmoles/mg protein incorporated.

System: Synthesis: Precursor:	Liver Mitochondria		Liver Microsomes		Brain Mitochondria	
	Protein (1)	Glycoprotein (2)	Protein (1)	Glycoprotein (2)	Protein (1)	Glycoprotein (2)
Control	8.4	6.8	4.4	5.6	12.0	1.2
"0" time	0.4	0.2	0.3	0.3	0.6	0.1
Boil Control	0.2	0.2	0.2	0.4	0.5	0.1
+2 x $10^{-3}\text{M}$ Warfarin	25.9	14.0	4.9	5.6	12.0	1.2
1 x $10^{-3}\text{M}$ Warfarin	14.1	9.6	4.6	5.6	12.0	1.2
2 x $10^{-4}\text{M}$ Warfarin	10.5	8.0	4.4	5.6	12.0	1.2
2 x $10^{-5}\text{M}$ Warfarin	8.8	6.8	4.4	5.6	12.0	1.2
2 x $10^{-6}\text{M}$ Warfarin	8.4	6.8	4.4	5.6	12.0	1.2
2 x $10^{-7}\text{M}$ Warfarin	8.4	6.8	4.4	5.6	12.0	1.2
+2 x $10^{-3}\text{M}$ Vitamin K <sub>1</sub>	40.2	42.2	5.2	12.4	28.0	2.2
+1 x $10^{-3}\text{M}$ Vitamin K <sub>1</sub>	24.4	31.2	4.6	8.2	21.0	2.0
+2 x $10^{-4}\text{M}$ Vitamin K <sub>1</sub>	18.3	22.1	4.4	5.9	18.0	1.4
+2 x $10^{-5}\text{M}$ Vitamin K <sub>1</sub>	17.1	16.0	4.4	5.6	14.0	1.2
+2 x $10^{-6}\text{M}$ Vitamin K <sub>1</sub>	14.2	6.9	4.4	5.6	12.0	1.2
+2 x $10^{-7}\text{M}$ Vitamin K <sub>1</sub>	8.5	6.8	4.4	5.6	12.0	1.2
100 $\mu\text{g/ml}$ chloramphenicol	2.4	5.3	4.4	5.6	---	---
250 $\mu\text{g/ml}$ chloramphenicol	2.1	5.0	4.5	5.8	---	---
2 x $10^{-5}\text{M}$ Warfarin	4.4	7.0	4.8	5.7	---	---
+100 $\mu\text{g/ml}$ chloramphenicol	2.9	6.0	4.7	5.6	---	---
2 x $10^{-3}\text{M}$ Warfarin	6.2	21.0	5.1	12.3	---	---
+250 $\mu\text{g/ml}$ chloramphenicol	4.9	19.0	5.1	12.4	---	---
2 x $10^{-3}\text{M}$ Vitamin K <sub>1</sub>	8.4	6.8	2.2	4.5	---	---
+250 $\mu\text{g/ml}$ chloramphenicol	8.5	6.9	1.8	4.0	---	---
2 x $10^{-5}\text{M}$ Warfarin	26.1	14.1	2.5	4.5	---	---
+100 $\mu\text{g/ml}$ cycloheximide	25.9	14.0	2.3	4.2	---	---
2 x $10^{-3}\text{M}$ Warfarin	41.0	40.9	2.6	9.6	---	---
+250 $\mu\text{g/ml}$ cycloheximide	40.3	42.3	2.3	9.0	---	---

(1) L-leucine- $^{14}\text{C}$ #, (2) glucosamine- $^{14}\text{C}$ +, (3) UDP-glucose- $^{14}\text{C}$ ++

Table 1. In each instance the mitochondria or microsomes were incubated in the designated system with the indicated labeled compound for 1 hour at 37°C.

\*The medium contained 10 mM  $MgCl_2$ , 5 mM sodium phosphate (pH 7.6), 50 mM Tris (hydroxymethyl) amino methane (pH 7.6), 5 mM phosphoenol pyruvate, 20  $\mu g$  of pyruvic kinase, 2 mM adenosine triphosphate, 2 mM EDTA, 22.5 mg/ml of a complete amino acid mixture minus leucine, 10  $\mu l$  of the labelled compound, 4 to 10 mg of mitochondrial or microsomal protein, and 0.154 M KCl to a final volume of 240  $\mu l$ . The liver microsomal assays also contained guanosine triphosphate (0.2 mM) and approximately 2 mg of pH 5 enzymes to a final volume of 300  $\mu l$ . #Uniformly labeled L-leucine- $^{14}C$  (0.2  $\mu Ci$ ). +Uniformly labeled glucosamine- $^{14}C$  (0.2  $\mu Ci$ ). ++Uniformly labeled uridine diphosphate glucose- $^{14}C$  (0.2  $\mu Ci$ ). Dashed lines indicate the experiment was not performed.

protein synthesis (Table 1) with vitamin  $K_1$ . At  $2 \times 10^{-3}$  M vitamin  $K_1$  a 5-fold increase in the incorporation of l-leucine- $^{14}C$  into protein and a 7-fold increase in glucosamine- $^{14}C$  and UDP-glucose- $^{14}C$  incorporation into glycoprotein was found. These increases followed a dose response curve; higher concentrations of vitamin  $K_1$  showed only a slight increase in liver microsomal l-leucine- $^{14}C$  incorporation and a 2-fold increase in liver microsomal glucosamine- $^{14}C$  incorporation and a 2-fold increase in both l-leucine- $^{14}C$  and glucosamine- $^{14}C$  incorporation in brain mitochondria. Thus the vitamin  $K_1$  accelerates protein and glycoprotein synthesis with the greatest acceleration in the isolated rat liver mitochondria.

Warfarin, which presumably acts in vivo as a competitive inhibitor of vitamin K, also accelerated protein and glycoprotein synthesis in rat liver mitochondria (Table 1). The increases with warfarin compared to similar concentrations of vitamin K are not as great; only a 3-fold increase in l-leucine- $^{14}C$  incorporation and a 2-fold increase in monosaccharide incorporation occurred. No effects of warfarin occurred in the liver microsomes or brain mitochondria.

Chloramphenicol inhibits mitochondrial protein and glycoprotein synthesis (20) but has little effect on microsomal protein synthesis. The present data indicate that the inhibition of isolated rat liver mitochondrial protein synthesis caused by chloramphenicol cannot be reversed substantially by vitamin  $K_1$  or warfarin but 50 percent of the response of glucosamine- $^{14}C$  incorporation with high levels of vitamin  $K_1$  was obtained in the presence of chloramphenicol

(Table 1). No effect on rat liver microsomal protein or glycoprotein synthesis was observed with chloramphenicol and the 2-fold increase in microsomal incorporation of glucosamine- $^{14}\text{C}$  with vitamin  $\text{K}_1$  was unaffected.

Cycloheximide at concentrations of 100  $\mu\text{g/ml}$  to 250  $\mu\text{g/ml}$  does not effect the acceleration of protein or glycoprotein synthesis found with warfarin and vitamin  $\text{K}_1$  in rat liver mitochondria. These concentrations of cycloheximide inhibit microsomal protein and glycoprotein synthesis and depress the microsomal acceleration of glucosamine- $^{14}\text{C}$  incorporation by vitamin  $\text{K}_1$  by 50 percent (Table 1).

The time course of acceleration of protein and glycoprotein synthesis by vitamin  $\text{K}_1$  and warfarin in isolated rat liver mitochondria was observed along




Figure 1. Time Course of Acceleration of Protein and Glycoprotein Synthesis by Vitamin  $\text{K}_1$  and Warfarin in Isolated Rat Liver Mitochondria. Data are p moles/mg protein. Warfarin and vitamin  $\text{K}_1$  final concentrations were  $2 \times 10^{-3}$  M. The same system for macromolecular synthesis was employed as described in Table 1. Concentrations of labelled compounds were as given in Table 1 for leucine- $^{14}\text{C}$  and glucosamine- $^{14}\text{C}$ .  $0.5 \mu\text{Ci}$  of uridine- $^3\text{H}$  and  $0.5 \mu\text{Ci}$  of thymidine- $^3\text{H}$  were added to the complete system for RNA and DNA synthesis. Macromolecular bound radioactivity was determined as described in Materials and Methods.

with the effect of vitamin K<sub>1</sub> and warfarin on rat liver mitochondrial RNA and DNA synthesis (Fig. 1). Leucine-<sup>14</sup>C and glucosamine-<sup>14</sup>C incorporation in isolated rat liver mitochondria by warfarin and vitamin K<sub>1</sub> occurred as early as the first 20 minutes of incubation and occurred in a more or less linear fashion thereafter (Fig. 1).

The data presented in Table 2 indicate that in L5178Y mouse leukemic cells, macromolecular synthesis was severely inhibited by high concentration of vitamin K<sub>1</sub> and warfarin. L5178Y cells were grown in Fischer medium plus 10 percent horse serum in suspension culture as previously described (25, 26). The cells, harvested in logarithmic growth, were resuspended in Fischer medium plus the required radioactively labeled precursor, in the presence or absence of warfarin or vitamin K<sub>1</sub>. The results in Table 2 indicate that RNA, DNA, protein and glycoprotein synthesis was inhibited by concentrations of 10<sup>-2</sup> to 10<sup>-3</sup> of warfarin or vitamin K<sub>1</sub>. In general the vitamin K<sub>1</sub> was more toxic at

Table 2. Inhibitory Effect of Warfarin and Vitamin K<sub>1</sub> on Macromolecular Synthesis in L5178Y Cells. Data are pmoles/mg protein.

Precursor	Uridine-H <sup>3</sup>	Thymidine-H <sup>3</sup>	Leucine- <sup>14</sup> C	Fucose-H <sup>3</sup>
Control	12.4	101	40	4.0
1 x 10 <sup>-2</sup> M Warfarin	2.6	9	16	2.1
5 x 10 <sup>-3</sup> M Warfarin	5.8	12	20	2.6
2 x 10 <sup>-3</sup> M Warfarin	7.9	68	25	3.7
1 x 10 <sup>-3</sup> M Warfarin	11.9	101	36	4.1
1 x 10 <sup>-2</sup> M Vitamin K <sub>1</sub>	0.4	4	3	1.6
5 x 10 <sup>-3</sup> M Vitamin K <sub>1</sub>	0.5	5	5	1.7
2 x 10 <sup>-3</sup> M Vitamin K <sub>1</sub>	1.6	8	12	1.8
1 x 10 <sup>-3</sup> M Vitamin K <sub>1</sub>	2.3	16	12	2.4

Table 2. Inhibitory effect of warfarin and vitamin K<sub>1</sub> on macromolecular synthesis in L5178Y cells. Data are expressed as p moles/mg protein. Logarithmic L5178Y cells (10<sup>5</sup> cells/ml) were incubated at 37°C for 60 minutes in Fischer medium plus the indicated labeled compound to a final volume of 0.5 ml. The amount and specific activity of each radioactive compound was: leucine-<sup>14</sup>C (0.3 µCi), 1-fucose-<sup>3</sup>H (0.5 µCi), uridine-<sup>3</sup>H (1.0 µCi) and thymidine-<sup>3</sup>H (1.0 µCi). Macromolecular bound radioactivity was determined as given in the Materials and Methods.

equimolar concentrations than the warfarin.

The results presented herein indicate that vitamin K<sub>1</sub> and its analogue warfarin accelerate protein and glycoprotein synthesis but not DNA or RNA synthesis in isolated rat liver mitochondria; vitamin K<sub>1</sub> had a greater effect than warfarin. The fact remains that in a normal (i.e. not a vitamin K deficient) rat liver mitochondrial system, vitamin K<sub>1</sub> at  $2 \times 10^{-3}$  M increases protein synthesis 5 fold and glycoprotein synthesis 7 fold; the implications of this are of great importance to the mechanism of vitamin K action, mitochondrial autonomy, and extracytoplasmic protein and glycoprotein synthesis. That the effects reported herein were due to vitamin K and warfarin was shown by assaying the suspending vehicles for the two compounds and photo-inactivated Aquamephyton in each of the systems. In every instance these assays did not significantly differ from the controls. Thus the results reported are due to the vitamin K<sub>1</sub> and warfarin molecules.

#### REFERENCES

1. Alkjaersig, N. and Seegers, W. H., *Am. J. Phys.* 183, 111 (1955).
2. Goswami, P. and Munro, H. N., *Biochim. Biophys. Acta* 55, 410 (1962).
3. Hill, R. B., Gaetani, S., Paolucci, A. M., Rao, P.B.R., Alden, R., Ranhotra, G. S., Shaw, D. V., Shaw, V. K., and Johnson, B. C., *J. Biol. Chem.* 243, 3930 (1968).
4. Martius, C. and Nitz-Litzow, D., *Biochim. Biophys. Acta* 13, 289 (1954).
5. Paolucci, A. M., Rama Rao, P. B., and Johnson, B. C., *J. Nutr.* 81, 17 (1963).
6. Kipfer, K. and Olson, R. E., *Biochem. Biophys. Res. Comm.* 38, 1041 (1970).
7. Suttie, J. W., *Fed. Proc.* 28, 5 (Sept-Oct, 1969).
8. Sinclair, J. H. and B. J. Stevens *Proc. Natl. Acad. Sci., U.S.* 56, 508 (1966).
9. Luck, K.J.L., and Reich, E., *Proc. Natl. Acad. Sci., U.S.* 52, 931 (1964).
10. Barnett, W. E., Brown, D. H., and Epler, J. L., *Proc. Natl. Acad. Sci., U.S.* 57, 1775 (1967).
11. F. L. Bygrave, and Kaiser, W., *European J. Biochem.* 8, 16 (1969).
12. Gross, N. J., Getz, G. S., and Rabinowitz, M., *J. Biol. Chem.* 244, 1552 (1969).
13. Bosmann, H. B., and Case, K. R., *Biochem. Biophys. Res. Commun.* 36, 830 (1969).
14. Bosmann, H. B., and Hemsworth, B. A., *J. Biol. Chem.* 245, 363 (1970).
15. Neupert, W., Brdiczka, D., and Bucher, T., *Biochem. Biophys. Res. Commun.* 27, 488 (1967).
16. Beattie, D. S., Basford, R. E., and Koritz, S. B., *Biochemistry* 6, 3099 (1967).
17. Roodyn, D. B., Suttie, J. W., and Work, T. S., *Biochem. J.* 83, 29 (1962).
18. Kadenbach, B., *Biochim. Biophys. Acta* 134, 430 (1967).
19. Bosmann, H. B. and Martin, S. S., *Science* 164, 190 (1969).

20. Bosmann, H. B., and Winston, R. A. Submitted.
21. Winston, R. A., and Bosmann, H. B., Fed. Proc. 29, 941 abs (1970).
22. Schneider, W. C. and Hogeboom, G. H., J. Biol. Chem. 183, 123 (1950).
23. Schneider, W. C. and Kuff, E. L., J. Biol. Chem. 244, 4843 (1969).
24. Lowry, O. H., Rosebrough, J., Farr, A. A., and Randall, R. J., J. Biol. Chem. 193, 266 (1951).
25. Bosmann, H. B., and Bernacki, R., J. Exp. Cell Res., in press.
26. Bernacki, R. J., and Bosmann, H. B., Fed. Proc. 29, 783 (abstract) (1970).